Patent details

Basic Information

Publication number:

EP2068938

PCT Application Number:

PCT/US/2007/078978

Type:

European Patent Granted for LU

Legal Status:

Lapsed

Application number:

EP078428422

PCT Publication Number:

WO/2008/036792

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

OPTIMIZATION OF THE TREATMENT OF PHILADELPHIA-POSITIVE LEUKEMIA WITH ABL TYROSINE KINASE INHIBITOR IMATINIB

French Title of Invention:

OPTIMISATION DE TRAITEMENT DE LA LEUCÉMIE PHILADELPHIE POSITIVE AVEC L'INHIBITEUR DE TYROSINE KINASE ABL IMATINIB

German Title of Invention:

OPTIMIERUNG DER BEHANDLUNG PHILADELPHIA-POSITIVER LEUKÄMIE MIT ABL-TYROSINKINASEHEMMER IMATINIB

SPC Number:

Dates

Filing date:

20/09/2007

Grant date:

19/01/2011

EP Publication Date:

19/01/2011

PCT Publication Date:

27/03/2008

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

17/06/2009

EP B1 Publication Date:

19/01/2011

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

20/09/2014

Expiration date:

20/09/2027

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

20/09/2007

 

 

Name:

Novartis AG

Address:

Lichtstrasse 35, 4056 Basel, Switzerland (CH)

Inventor

1

Name:

MAHON Francois-Xavier

Address:

France (FR)

2

Name:

MOLIMARD Mathieu

Address:

France (FR)

3

Name:

PICARD Stéphane

Address:

France (FR)

4

Name:

WANG Yanfeng

Address:

United States (US)

5

Name:

GATHMANN Insa

Address:

Switzerland (CH)

Priority

1

Priority Number:

826622 P

Priority Date:

22/09/2006

Priority Country:

United States (US)

2

Priority Number:

828278 P

Priority Date:

05/10/2006

Priority Country:

United States (US)

Classification

Main IPC Class:

A61K 49/00;

Filing date	Document type	Number of pages